Top

Published in:

Open Access 01-12-2006 | Review

Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology – an update for the surgical oncologist

Authors: Ewen A Griffiths, Susan A Pritchard, Nicholas P Mapstone, Ian M Welch

Published in: World Journal of Surgical Oncology | Issue 1/2006

Abstract

Adenocarcinoma of the oesophagus and gastro-oesophageal junction are rapidly increasing in incidence and have a well described sequence of carcinogenesis: the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. During recent years there have been changes in the knowledge surrounding disease progression, cancer management and histopathology specimen reporting. Tumours around the gastro-oesophageal junction (GOJ) pose several specific challenges. Numerous difficulties arise when the existing TNM staging systems for gastric and oesophageal cancers are applied to GOJ tumours. The issues facing the current TNM staging and GOJ tumour classification systems are reviewed in this article. Recent evidence regarding the importance of several histopathologically derived prognostic factors, such as circumferential resection margin status and lymph node metastases, have implications for specimen reporting. With the rising use of multimodal treatments for oesophageal cancer it is important that the response of the tumour to this therapy is carefully documented pathologically. In addition, several controversial and novel areas such as endoscopic mucosal resection, lymph node micrometastases and the sentinel node concept are being studied. We aim to review these aspects, with special relevance to oesophageal and gastro-oesophageal cancer specimen reporting, to update the surgical oncologist with an interest in upper gastrointestinal cancer.

Available only for authorised users

Blot WJ, Devesa SS, Kneller RW, Fraumeni JF: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. Jama. 1991, 265 (10): 1287-1289. 10.1001/jama.265.10.1287.PubMed

Branagan G, Davies N: Early impact of centralization of oesophageal cancer surgery services. Br J Surg. 2004, 91 (12): 1630-1632. 10.1002/bjs.4753.PubMed

Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, Van Raemdonck D: Quality in the surgical treatment of cancer of the esophagus and gastroesophageal junction. Eur J Surg Oncol. 2005, 31 (6): 587-594. 10.1016/j.ejso.2005.02.010.PubMed

Metzger R, Bollschweiler E, Vallbohmer D, Maish M, DeMeester TR, Holscher AH: High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality?. Dis Esophagus. 2004, 17 (4): 310-314. 10.1111/j.1442-2050.2004.00431.x.PubMed

Gillison EW, Powell J, McConkey CC, Spychal RT: Surgical workload and outcome after resection for carcinoma of the oesophagus and cardia. Br J Surg. 2002, 89 (3): 344-348. 10.1046/j.0007-1323.2001.02015.x.PubMed

Guidance on Commissioning Cancer Services: Improving Outcomes in Upper Gastrointestinal Cancers. 2001, London , Department of Health

Melville A, Morris E, Forman D, Eastwood A: Management of upper gastrointestinal cancers. Qual Health Care. 2001, 10 (1): 57-64. 10.1136/qhc.10.1.57.PubMedCentralPubMed

Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. 2005, British Society of Gastroenterology

Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ: An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology. 1993, 105 (1): 40-50.PubMed

10.

Flejou JF: Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut. 2005, 54 Suppl 1: i6-12. 10.1136/gut.2004.041525.PubMed

11.

Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC: Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983, 14 (11): 931-968.PubMed

12.

Ormsby AH, Petras RE, Henricks WH, Rice TW, Rybicki LA, Richter JE, Goldblum JR: Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut. 2002, 51 (5): 671-676. 10.1136/gut.51.5.671.PubMedCentralPubMed

13.

Robert ME: Defining dysplasia in Barrett esophagus. J Clin Gastroenterol. 2003, 36 (5 Suppl): S19-25; discussion S26-8. 10.1097/00004836-200305001-00004.PubMed

14.

Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Flejou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H: The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000, 47 (2): 251-255. 10.1136/gut.47.2.251.PubMedCentralPubMed

15.

Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, Shyr Y, Washington K: Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001, 32 (4): 368-378. 10.1053/hupa.2001.23510.PubMed

16.

Allum WH, Griffin SM, Watson A, Colin-Jones D: Guidelines for the management of oesophageal and gastric cancer. Gut. 2002, 50 Suppl 5: v1-23.PubMed

17.

Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR: The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol. 2000, 95 (12): 3383-3387. 10.1111/j.1572-0241.2000.03348.x.PubMed

18.

Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, Seidel UJ, Sonnenberg A: Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2001, 120 (7): 1607-1619. 10.1053/gast.2001.25065.PubMed

19.

Edwards MJ, Gable DR, Lentsch AB, Richardson JD: The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. Ann Surg. 1996, 223 (5): 585-9; discussion 589-91. 10.1097/00000658-199605000-00014.PubMedCentralPubMed

20.

Rice TW, Falk GW, Achkar E, Petras RE: Surgical management of high-grade dysplasia in Barrett's esophagus. Am J Gastroenterol. 1993, 88 (11): 1832-1836.PubMed

21.

Dar MS, Goldblum JR, Rice TW, Falk GW: Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy?. Gut. 2003, 52 (4): 486-489. 10.1136/gut.52.4.486.PubMedCentralPubMed

22.

Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, Anderson MA, Petterson TM, Burgart LJ: Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001, 120 (7): 1630-1639. 10.1053/gast.2001.25111.PubMed

23.

Weston AP, Badr AS, Hassanein RS: Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol. 1999, 94 (12): 3413-3419. 10.1111/j.1572-0241.1999.01602.x.PubMed

24.

Al-Kasspooles MF, Hill HC, Nava HR, Smith JL, Douglass HO, Gibbs JF: High-grade dysplasia within Barrett's esophagus: controversies regarding clinical opinions and approaches. Ann Surg Oncol. 2002, 9 (3): 222-227. 10.1245/aso.2002.9.3.222.PubMed

25.

Mapstone NP: Minimum dataset for oesophageal carcinoma histopathology reports. 1998, London , Royal College of Pathologists

26.

Ibrahim NB: ACP. Best Practice No 155. Guidelines for handling oesophageal biopsies and resection specimens and their reporting. J Clin Pathol. 2000, 53 (2): 89-94. 10.1136/jcp.53.2.89.PubMedCentralPubMed

27.

Lee RG, Compton CC: Protocol for the examination of specimens removed from patients with esophageal carcinoma. A basis for checklists. The Cancer Committee, College of American Pathologists, and the Task Force on the Examination of Specimens From Patients With Esophageal Cancer. Arch Pathol Lab Med. 1997, 121 (9): 925-929.PubMed

28.

Burroughs SH, Biffin AH, Pye JK, Williams GT: Oesophageal and gastric cancer pathology reporting: a regional audit. J Clin Pathol. 1999, 52 (6): 435-439.PubMedCentralPubMed

29.

King PM, Blazeby JM, Gupta J, Alderson D, Moorghen M: Upper gastrointestinal cancer pathology reporting: a regional audit to compare standards with minimum datasets. J Clin Pathol. 2004, 57 (7): 702-705. 10.1136/jcp.2003.013326.PubMedCentralPubMed

30.

Devesa SS, Blot WJ, Fraumeni JF: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998, 83 (10): 2049-2053. 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2.PubMed

31.

Devesa SS, Fraumeni JF: The rising incidence of gastric cardia cancer. J Natl Cancer Inst. 1999, 91 (9): 747-749. 10.1093/jnci/91.9.747.PubMed

32.

Dolan K, Sutton R, Walker SJ, Morris AI, Campbell F, Williams EM: New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer. 1999, 80 (5-6): 834-842. 10.1038/sj.bjc.6690429.PubMedCentralPubMed

33.

Siewert JR, Feith M, Stein HJ: Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol. 2005, 90 (3): 139-46; discussion 146. 10.1002/jso.20218.PubMed

34.

Sobin LH: International Union Against Cancer (UICC): TNM Classification of Malignant Tumours. 2002, New York , Wiley-Liss, 6th

35.

Siewert JR, Stein HJ: Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998, 85 (11): 1457-1459. 10.1046/j.1365-2168.1998.00940.x.PubMed

36.

Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW: Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg. 1999, 86 (4): 529-535. 10.1046/j.1365-2168.1999.01082.x.PubMed

37.

Ellis FH, Heatley GJ, Balogh K: Proposal for improved staging criteria for carcinoma of the esophagus and cardia. Eur J Cardiothorac Surg. 1997, 12 (3): 361-4; discussion 364-5. 10.1016/S1010-7940(97)00178-4.PubMed

38.

van de Ven C, De Leyn P, Coosemans W, Van Raemdonck D, Lerut T: Three-field lymphadenectomy and pattern of lymph node spread in T3 adenocarcinoma of the distal esophagus and the gastro-esophageal junction. Eur J Cardiothorac Surg. 1999, 15 (6): 769-773. 10.1016/S1010-7940(99)00122-0.PubMed

39.

Lagarde SM, ten Kate FJ, Reitsma JB, Busch OR, van Lanschot JJ: Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2006, 24 (26): 4347-4355. 10.1200/JCO.2005.04.9445.PubMed

40.

de Manzoni G, Pedrazzani C, Verlato G, Roviello F, Pasini F, Pugliese R, Cordiano C: Comparison of old and new TNM systems for nodal staging in adenocarcinoma of the gastro-oesophageal junction. Br J Surg. 2004, 91 (3): 296-303. 10.1002/bjs.4431.PubMed

41.

Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA: Treatment outcomes of resected esophageal cancer. Ann Surg. 2002, 236 (3): 376-84; discussion 384-5. 10.1097/00000658-200209000-00014.PubMedCentralPubMed

42.

Siewert JR, Feith M, Werner M, Stein HJ: Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000, 232 (3): 353-361. 10.1097/00000658-200009000-00007.

43.

Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM: Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002, 95 (7): 1434-1443. 10.1002/cncr.10868.PubMed

44.

Vallbohmer D, Lenz HJ: Predictive and prognostic molecular markers in outcome of esophageal cancer. Diseases of the Esophagus. 2006, 19 (6): 425-432. 10.1111/j.1442-2050.2006.00622.x.PubMed

45.

Hermanek P, Wittekind C: The pathologist and the residual tumor (R) classification. Pathol Res Pract. 1994, 190 (2): 115-123.PubMed

46.

Law S, Arcilla C, Chu KM, Wong J: The significance of histologically infiltrated resection margin after esophagectomy for esophageal cancer. Am J Surg. 1998, 176 (3): 286-290. 10.1016/S0002-9610(98)00140-8.PubMed

47.

Mulligan ED, Dunne B, Griffin M, Keeling N, Reynolds JV: Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit. Eur J Surg Oncol. 2004, 30 (3): 313-317. 10.1016/j.ejso.2003.11.009.PubMed

48.

Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon MF, Quirke P: Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet. 1994, 344 (8924): 707-711. 10.1016/S0140-6736(94)92206-3.PubMed

49.

Wibe A, Rendedal PR, Svensson E, Norstein J, Eide TJ, Myrvold HE, Soreide O: Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg. 2002, 89 (3): 327-334. 10.1046/j.0007-1323.2001.02024.x.PubMed

50.

Sagar PM, Johnston D, McMahon MJ, Dixon MF, Quirke P: Significance of circumferential resection margin involvement after oesophagectomy for cancer. Br J Surg. 1993, 80 (11): 1386-1388.PubMed

51.

Dexter SP, Sue-Ling H, McMahon MJ, Quirke P, Mapstone N, Martin IG: Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut. 2001, 48 (5): 667-670. 10.1136/gut.48.5.667.PubMedCentralPubMed

52.

Griffiths EA, Brummell Z, Gorthi G, Pritchard SA, Welch IM: The prognostic value of circumferential resection margin involvement in oesophageal malignancy. Eur J Surg Oncol. 2006, 32 (4): 413-419. 10.1016/j.ejso.2005.11.024.PubMed

53.

Zafirellis K, Dolan K, Fountoulakis A, Dexter SP, Martin IG, Sue-Ling HM: Multivariate analysis of clinical, operative and pathologic features of esophageal cancer: who needs adjuvant therapy?. Dis Esophagus. 2002, 15 (2): 155-159. 10.1046/j.1442-2050.2002.00230.x.PubMed

54.

Khan OA, Fitzgerald JJ, Soomro I, Beggs FD, Morgan WE, Duffy JP: Prognostic significance of circumferential resection margin involvement following oesophagectomy for cancer. Br J Cancer. 2003, 88 (10): 1549-1552. 10.1038/sj.bjc.6600931.PubMedCentralPubMed

55.

Merchant NB, Guillem JG, Paty PB, Enker WE, Minsky BD, Quan SH, Wong D, Cohen AM: T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg. 1999, 3 (6): 642-647. 10.1016/S1091-255X(99)80087-0.PubMed

56.

Saha S, Dehn TC: Ratio of invaded to removed lymph nodes as a prognostic factor in adenocarcinoma of the distal esophagus and esophagogastric junction. Dis Esophagus. 2001, 14 (1): 32-36. 10.1111/j.1442-2050.2001.00148.x.PubMed

57.

Ludeman L, Shepherd NA: Serosal involvement in gastrointestinal cancer: its assessment and significance. Histopathology. 2005, 47 (2): 123-131. 10.1111/j.1365-2559.2005.02189.x.PubMed

58.

Birbeck KF, Macklin CP, Tiffin NJ, Parsons W, Dixon MF, Mapstone NP, Abbott CR, Scott N, Finan PJ, Johnston D, Quirke P: Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg. 2002, 235 (4): 449-457. 10.1097/00000658-200204000-00001.PubMedCentralPubMed

59.

Nagtegaal ID, van Krieken JH: The role of pathologists in the quality control of diagnosis and treatment of rectal cancer-an overview. Eur J Cancer. 2002, 38 (7): 964-972. 10.1016/S0959-8049(02)00056-4.PubMed

60.

Dixon MF: Minimum dataset for gastric cancer histopathology reports. Standards and minimum datasets for reporting cancers. 2000, London , Royal College of Pathologists

61.

Watanabe M, Kuwano H, Araki K, Kawaguchi H, Saeki H, Kitamura K, Ohno S, Sugimachi K: Prognostic factors in patients with submucosal carcinoma of the oesophagus. Br J Cancer. 2000, 83 (5): 609-613. 10.1054/bjoc.2000.1288.PubMedCentralPubMed

62.

Brucher BL, Stein HJ, Werner M, Siewert JR: Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer. 2001, 92 (8): 2228-2233. 10.1002/1097-0142(20011015)92:8<2228::AID-CNCR1567>3.0.CO;2-4.PubMed

63.

von Rahden BH, Stein HJ, Feith M, Becker K, Siewert JR: Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2005, 23 (4): 874-879. 10.1200/JCO.2005.12.151.PubMed

64.

Roder JD, Busch R, Stein HJ, Fink U, Siewert JR: Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg. 1994, 81 (3): 410-413.PubMed

65.

Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U: Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 2001, 234 (3): 360-7; discussion 368-9. 10.1097/00000658-200109000-00010.PubMedCentralPubMed

66.

TNM Supplement: A Commentary on Uniform Use. Edited by: Wittekind C GFHRVPSLHHDE. 2003, Wiley-Liss, 3rd Edition

67.

Fumagilli U: Resective surgery for cancer of thoracic esophagus. Results of a consensus conference of the International Society for Diseases of the Esophagus. Dis Esophagus. 1996, 9 (Suppl. 1): 30-38.

68.

Holscher AH, Bollschweiler E, Bumm R, Bartels H, Hofler H, Siewert JR: Prognostic factors of resected adenocarcinoma of the esophagus. Surgery. 1995, 118 (5): 845-855. 10.1016/S0039-6060(05)80275-2.PubMed

69.

Tachibana M, Dhar DK, Kinugasa S, Kotoh T, Shibakita M, Ohno S, Masunaga R, Kubota H, Nagasue N: Esophageal cancer with distant lymph node metastasis: prognostic significance of metastatic lymph node ratio. J Clin Gastroenterol. 2000, 31 (4): 318-322. 10.1097/00004836-200012000-00010.PubMed

70.

Verrill C, Carr NJ, Wilkinson-Smith E, Seel EH: Histopathological assessment of lymph nodes in colorectal carcinoma: does triple levelling detect significantly more metastases?. J Clin Pathol. 2004, 57 (11): 1165-1167. 10.1136/jcp.2004.018002.PubMedCentralPubMed

71.

Lagarde SM, ten Kate FJ, de Boer DJ, Busch OR, Obertop H, van Lanschot JJ: Extracapsular lymph node involvement in node-positive patients with adenocarcinoma of the distal esophagus or gastroesophageal junction. Am J Surg Pathol. 2006, 30 (2): 171-176. 10.1097/01.pas.0000189182.92815.12.PubMed

72.

Lerut T, Coosemans W, Decker G, De Leyn P, Ectors N, Fieuws S, Moons J, Nafteux P, Van Raemdonck D: Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg. 2003, 126 (4): 1121-1128. 10.1016/S0022-5223(03)00941-3.PubMed

73.

Heeren PA, Kelder W, Blondeel I, van Westreenen HL, Hollema H, Plukker JT: Prognostic value of nodal micrometastases in patients with cancer of the gastro-oesophageal junction. Eur J Surg Oncol. 2005, 31 (3): 270-276. 10.1016/j.ejso.2004.12.001.PubMed

74.

Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, Pantel K: Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997, 337 (17): 1188-1194. 10.1056/NEJM199710233371702.PubMed

75.

Komukai S, Nishimaki T, Watanabe H, Ajioka Y, Suzuki T, Hatakeyama K: Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. Surgery. 2000, 127 (1): 40-46. 10.1067/msy.2000.102754.PubMed

76.

Sato F, Shimada Y, Li Z, Watanabe G, Maeda M, Imamura M: Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma. Br J Surg. 2001, 88 (3): 426-432. 10.1046/j.1365-2168.2001.01687.x.PubMed

77.

Nakamura T, Ide H, Eguchi R, Hayashi K, Ota M, Takasaki K: Clinical implications of lymph node micrometastasis in patients with histologically node-negative (pN0) esophageal carcinoma. J Surg Oncol. 2002, 79 (4): 224-229. 10.1002/jso.10080.PubMed

78.

Lamb PJ, Griffin SM, Burt AD, Lloyd J, Karat D, Hayes N: Sentinel node biopsy to evaluate the metastatic dissemination of oesophageal adenocarcinoma. Br J Surg. 2005, 92 (1): 60-67. 10.1002/bjs.4693.PubMed

79.

Hosch SB, Stoecklein NH, Pichlmeier U, Rehders A, Scheunemann P, Niendorf A, Knoefel WT, Izbicki JR: Esophageal cancer: the mode of lymphatic tumor cell spread and its prognostic significance. J Clin Oncol. 2001, 19 (7): 1970-1975.PubMed

80.

Burian M, Stein HJ, Sendler A, Piert M, Nahrig J, Feith M, Siewert JR: Sentinel node detection in Barrett's and cardia cancer. Ann Surg Oncol. 2004, 11 (3 Suppl): 255S-8S.PubMed

81.

Barr H, Stone N, Rembacken B: Endoscopic therapy for Barrett's oesophagus. Gut. 2005, 54 (6): 875-884. 10.1136/gut.2004.047118.PubMedCentralPubMed

82.

Hull MJ, Mino-Kenudson M, Nishioka NS, Ban S, Sepehr A, Puricelli W, Nakatsuka L, Ota S, Shimizu M, Brugge WR, Lauwers GY: Endoscopic mucosal resection: an improved diagnostic procedure for early gastroesophageal epithelial neoplasms. Am J Surg Pathol. 2006, 30 (1): 114-118. 10.1097/01.pas.0000180438.56528.a0.PubMed

83.

Soetikno R, Kaltenbach T, Yeh R, Gotoda T: Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol. 2005, 23 (20): 4490-4498. 10.1200/JCO.2005.19.935.PubMed

84.

Vieth M, Stolte M: Pathology of early upper GI cancers. Best Pract Res Clin Gastroenterol. 2005, 19 (6): 857-869. 10.1016/j.bpg.2005.02.008.PubMed

85.

Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002, 359 (9319): 1727-1733. 10.1016/S0140-6736(02)08651-8.

86.

Naunheim KS, Petruska PJ, Roy TS, Schlueter JM, Kim H, Baue AE: Multimodality therapy for adenocarcinoma of the esophagus. Ann Thorac Surg. 1995, 59 (5): 1085-90; discussion 1090-1. 10.1016/0003-4975(95)00119-6.PubMed

87.

Vogel SB, Mendenhall WM, Sombeck MD, Marsh R, Woodward ER: Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg. 1995, 221 (6): 685-93; discussion 693-5. 10.1097/00000658-199506000-00008.PubMedCentralPubMed

88.

Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996, 335 (7): 462-467. 10.1056/NEJM199608153350702.PubMed

89.

Bailey SH, Bull DA, Harpole DH, Rentz JJ, Neumayer LA, Pappas TN, Daley J, Henderson WG, Krasnicka B, Khuri SF: Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg. 2003, 75 (1): 217-22; discussion 222. 10.1016/S0003-4975(02)04368-0.PubMed

90.

Abou-Jawde RM, Mekhail T, Adelstein DJ, Rybicki LA, Mazzone PJ, Caroll MA, Rice TW: Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer. Chest. 2005, 128 (1): 250-255. 10.1378/chest.128.1.250.PubMed

91.

Reynolds JV, Ravi N, Hollywood D, Kennedy MJ, Rowley S, Ryan A, Hughes N, Carey M, Byrne P: Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy. J Thorac Cardiovasc Surg. 2006, 132 (3): 549-555. 10.1016/j.jtcvs.2006.05.015.PubMed

92.

Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997, 337 (3): 161-167. 10.1056/NEJM199707173370304.PubMed

93.

Heath EI, Burtness BA, Heitmiller RF, Salem R, Kleinberg L, Knisely JP, Yang SC, Talamini MA, Kaufman HS, Canto MI, Topazian M, Wu TT, Olukayode K, Forastiere AA: Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol. 2000, 18 (4): 868-876.PubMed

94.

Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998, 339 (27): 1979-1984. 10.1056/NEJM199812313392704.PubMed

95.

Bates BA, Detterbeck FC, Bernard SA, Qaqish BF, Tepper JE: Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol. 1996, 14 (1): 156-163.PubMed

96.

Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M: Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005, 23 (19): 4330-4337. 10.1200/JCO.2005.05.017.PubMed

97.

Carey RW, Hilgenberg AD, Wilkins EW, Choi NC, Mathisen DJ, Grillo HC, Wain JC, Logan DL, Bromberg C: Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus. Cancer Invest. 1993, 11 (2): 99-105.PubMed

98.

Dunne B, Reynolds JV, Mulligan E, Kelly A, Griffin M: A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. J Clin Pathol. 2001, 54 (11): 841-845.PubMedCentralPubMed

99.

Suvarna SK, Stephenson TJ: A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. J Clin Pathol. 2002, 55 (9): 718-10.1136/jcp.55.9.718.PubMedCentralPubMed

100.

Hornick JL, Farraye FA, Odze RD: Prevalence and significance of prominent mucin pools in the esophagus post neoadjuvant chemoradiotherapy for Barrett's-associated adenocarcinoma. Am J Surg Pathol. 2006, 30 (1): 28-35. 10.1097/01.pas.0000174011.29816.fa.PubMed

101.

Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT: Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005, 103 (7): 1347-1355. 10.1002/cncr.20916.PubMed

102.

Darnton SJ, Allen SM, Edwards CW, Matthews HR: Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. J Clin Pathol. 1993, 46 (1): 51-55.PubMedCentralPubMed

103.

Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994, 73 (11): 2680-2686. 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C.PubMed

104.

Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA: Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005, 241 (5): 810-7; discussion 817-20. 10.1097/01.sla.0000161983.82345.85.PubMedCentralPubMed

105.

Chirieac LR, Swisher SG, Correa AM, Ajani JA, Komaki RR, Rashid A, Hamilton SR, Wu TT: Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005, 11 (6): 2229-2236. 10.1158/1078-0432.CCR-04-1840.PubMed

106.

Blazeby JM, Wilson L, Metcalfe C, Nicklin J, English R, Donovan JL: Analysis of clinical decision-making in multi-disciplinary cancer teams. Ann Oncol. 2005

107.

Stephens MR, Lewis WG, Brewster AE, Lord I, Blackshaw GR, Hodzovic I, Thomas GV, Roberts SA, Crosby TD, Gent C, Allison MC, Shute K: Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer. Dis Esophagus. 2006, 19 (3): 164-171. 10.1111/j.1442-2050.2006.00559.x.PubMed

108.

McBroom HM, Ramsay AD: The clinicopathological meeting. A means of auditing diagnostic performance. Am J Surg Pathol. 1993, 17 (1): 75-80. 10.1097/00000478-199301000-00009.PubMed

109.

Davies AR, Deans DAC, Penman I, Plevris JN, Fletcher J, Wall L, Phillips H, Gilmour H, Patel D, de Beaux A, Paterson-Brown S: The multidisciplinary team meeting improves staging accuracy and treatment selection for gastro-esophageal cancer. Diseases of the Esophagus. 2006, 19 (6): 496-503. 10.1111/j.1442-2050.2006.00629.x.PubMed

110.

Dresner SM, Lamb PJ, Bennett MK, Hayes N, Griffin SM: The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery. 2001, 129 (1): 103-109. 10.1067/msy.2001.110024.PubMed

111.

Thomas P, Doddoli C, Lienne P, Morati N, Thirion X, Garbe L, Giudicelli R, Fuentes P: Changing patterns and surgical results in adenocarcinoma of the oesophagus. Br J Surg. 1997, 84 (1): 119-125. 10.1002/bjs.1800840143.PubMed

112.

Rice TW, Blackstone EH, Rybicki LA, Adelstein DJ, Murthy SC, DeCamp MM, Goldblum JR: Refining esophageal cancer staging. J Thorac Cardiovasc Surg. 2003, 125 (5): 1103-1113. 10.1067/mtc.2003.170.PubMed

113.

Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE: Incidence and prognostic significance of vascular and neural invasion in squamous cell carcinomas of the esophagus. Int J Cancer. 1995, 61 (3): 333-336.PubMed

114.

Theunissen PH, Borchard F, Poortvliet DC: Histopathological evaluation of oesophageal carcinoma: the significance of venous invasion. Br J Surg. 1991, 78 (8): 930-932.PubMed

115.

Tanaka A, Matsumura E, Yosikawa H, Uchida T, Machidera N, Kubo R, Okuno K, Koh K, Watatani M, Yasutomi M: An evaluation of neural invasion in esophageal cancer. Surg Today. 1998, 28 (9): 873-878. 10.1007/s005950050245.PubMed

116.

Griffiths EA, Brummell Z, Gorthi G, Pritchard SA, Welch IM: Tumor length as a prognostic factor in esophageal malignancy: univariate and multivariate survival analyses. J Surg Oncol. 2006, 93 (4): 258-267. 10.1002/jso.20449.PubMed

117.

Langley SM, Alexiou C, Bailey DH, Weeden DF: The influence of perioperative blood transfusion on survival after esophageal resection for carcinoma. Ann Thorac Surg. 2002, 73 (6): 1704-1709. 10.1016/S0003-4975(02)03508-7.PubMed

118.

Robey-Cafferty SS, el-Naggar AK, Sahin AA, Bruner JM, Ro JY, Cleary KR: Prognostic factors in esophageal squamous carcinoma. A study of histologic features, blood group expression, and DNA ploidy. Am J Clin Pathol. 1991, 95 (6): 844-849.PubMed

119.

Roh MS, Lee JI, Choi PJ: Significance of circumferential resection margin involvement following esophagectomy for esophageal cancer. The Korean Journal of Pathology. 2004, 38: 23-28.

120.

Guidelines for the clinical and pathological studies on carcinoma of the esophagus. 1999, Tokyo , Japanese Society for Esophageal Disease

121.

Ichikura T, Ogawa T, Kawabata T, Chochi K, Sugasawa H, Mochizuki H: Is adenocarcinoma of the gastric cardia a distinct entity independent of subcardial carcinoma?. World J Surg. 2003, 27 (3): 334-338. 10.1007/s00268-002-6776-8.PubMed

Title: Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology – an update for the surgical oncologist
Authors: Ewen A Griffiths
Susan A Pritchard
Nicholas P Mapstone
Ian M Welch
Publication date: 01-12-2006
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2006
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-4-82

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology – an update for the surgical oncologist

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2006

Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents

Low grade Endometrial Stromal Sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases

Tactile-like corpuscles in gastric mucosa: a case report

Management of a patient with multiple recurrences of fibromatosis (desmoid tumor) of the breast involving the chest wall musculature

Abdominal wall implantation of hepatocellular carcinoma

Duodenoportal fistula caused by peptic ulcer after extended right hepatectomy for hilar cholangiocarcinoma